» Articles » PMID: 5294180

Studies on Vaccination Against Bacillary Dysentery. 3. Effective Oral Immunization Against Shigella Flexneri 2a in a Field Trial

Overview
Specialty Public Health
Date 1965 Jan 1
PMID 5294180
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

In May 1963 a live vaccine prepared from streptomycin-dependent Shigella flexneri 2a was administered to 355 soldiers stationed in an area of Yugoslavia in which bacillary dysentery was hyperendemic. Five oral doses were given every third day. 382 unvaccinated soldiers from the same unit served as controls. Both groups were closely followed up until 16 September.Examination of 1637 rectal swabs from the vaccinated and control groups indicated that vaccination did not affect the carrier rate. The morbidity from shigellae of serotypes not contained in the vaccine was the same in the two groups; but Sh. flexneri 2a caused dysentery in 5.5% of the control group but in none of the vaccinated soldiers-a statistically significant difference.A similar vaccine, given in a much lower dose, was also tried among soldiers of another unit; the dose was insufficient to confer protection.The authors conclude that the results of these field trials justify further studies with live Shigella vaccine.

Citing Articles

A Pentavalent LPS-Based Vaccine Candidate Is Safe and Immunogenic in Animal Models.

Ledov V, Golovina M, Alkhazova B, Lvov V, Kovalchuk A, Aparin P Vaccines (Basel). 2023; 11(2).

PMID: 36851223 PMC: 9966156. DOI: 10.3390/vaccines11020345.


From Kiyoshi Shiga to Present-Day Shigella Vaccines: A Historical Narrative Review.

Herrera C, Schmitt J, Chowdhry E, Riddle M Vaccines (Basel). 2022; 10(5).

PMID: 35632401 PMC: 9145194. DOI: 10.3390/vaccines10050645.


Shigella-Controlled Human Infection Models: Current and Future Perspectives.

Clarkson K, Porter C, Talaat K, Kapulu M, Chen W, Frenck Jr R Curr Top Microbiol Immunol. 2022; 445:257-313.

PMID: 35616717 PMC: 7616482. DOI: 10.1007/82_2021_248.


Towards a Four-Component GMMA-Based Vaccine against .

Micoli F, Nakakana U, Scorza F Vaccines (Basel). 2022; 10(2).

PMID: 35214786 PMC: 8880054. DOI: 10.3390/vaccines10020328.


Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints.

MacLennan C, Riddle M, Chen W, Talaat K, Jain V, Louis Bourgeois A Clin Infect Dis. 2019; 69(Suppl 8):S591-S595.

PMID: 31816065 PMC: 6901125. DOI: 10.1093/cid/ciz891.


References
1.
Mel D, TERZIN A, Vuksic L . Studies on vaccination against bacillary dysentery. 1. Immunization of mice against experimental Shigella infection. Bull World Health Organ. 1965; 32(5):633-6. PMC: 2555250. View

2.
Mel D, Papo R, TERZIN A, Vuksic L . Studies on vaccination against bacillary dysentery. 2. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials. Bull World Health Organ. 1965; 32(5):637-45. PMC: 2555254. View